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Rosacea is a chronic inflammatory skin disease of
unknown etiology. Although described centuries ago,
the pathophysiology of this disease is still poorly
understood. Epidemiological studies indicate a genetic
component, but a rosacea gene has not been identified
yet. Four subtypes and several variants of rosacea have
been described. It is still unclear whether these sub-
types represent a ‘‘developmental march’’ of different
stages or are merely part of a syndrome that develops
independently but overlaps clinically. Clinical and
histopathological characteristics of rosacea make it a
fascinating ‘‘human disease model’’ for learning about
the connection between the cutaneous vascular, nervous,
and immune systems. Innate immune mechanisms and
dysregulation of the neurovascular system are involved
in rosacea initiation and perpetuation, although the
complex network of primary induction and secondary
reaction of neuroimmune communication is still unclear.
Later, rosacea may result in fibrotic facial changes,
suggesting a strong connection between chronic inflam-
matory processes and skin fibrosis development. This
review highlights recent molecular (gene array) and
cellular findings and aims to integrate the different
body defense mechanisms into a modern concept of
rosacea pathophysiology.
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CLASSIFICATION AND EPIDEMIOLOGY OF ROSACEA
Rosacea is a common, almost exclusively facial inflammatory
skin disease characterized by erythema and telangiectasia
(erythematotelangiectatic rosacea, ETR, subtype I, RI), papu-
lopustular rosacea (PPR, subtype II, RII), and phymatous
rosacea (PhR, subtype III, RIII; Figure 1a). Ocular structures
may also be involved (ocular rosacea, subtype IV). Several
additional variants have been described (Wilkin et al., 2002,
2004), although their subdivision into the entity rosacea is not
yet clear. Rosacea prevalence is highest (between 2.7 and
10%) in patients of northern European or Celtic heritage
(Webster, 2009; Abram et al., 2010b; McAleer et al., 2010).
Humans with fair skin (Fitzpatrick skin phenotypes I–II) are
more likely to be affected, whereas Asians and African
Americans are less affected, indicating a genetic component
(Abram et al., 2010a). This is also supported by the finding
that often African Americans are affected when one parent is
of northern European origin (Steinhoff M, unpublished obser-
vation). Rosacea is more common among female patients,
and incidence peaks between the ages of 30 and 50 years.
Analyzing the molecular and protein profiles of the
different rosacea subtypes has increased our understanding
of rosacea pathophysiology and will continue to do so. Gene
array (Figure 1b and 2b) and subsequent real-time PCR
analysis (not shown) indicate that the clinically defined
subtypes of rosacea also differ in their gene profile. All
rosacea subtypes show a different gene profile compared
with healthy skin. Each subtype can be differentiated by a
selective gene profile (Figure 1b). Thus, the pathomechanisms
of the different subtypes may vary with respect to the
molecular pathways and molecules involved. Our gene array
analysis indicates that certain genes overlap, which means
that a developmental ‘‘march’’ among the different rosacea
subtypes can be assumed in most cases (Figure 1). Despite
that, it is still unclear whether patients in whom rosacea
becomes clinically apparent not earlier than in the PhR
subtype undergo a subclinical form of ETR and PPR.
Rosacea’s clinical features and trigger factors indicate a
complex dysregulation of inflammatory, vascular, and neuronal
systems at an early stage
The impact of a dysregulatory vascular system in rosacea
patients has long been hypothesized (Flint and Wilkin, 1994;
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Huggenberger and Detmar, 2011). Substantial evidence
indicates that sun exposure is important in the pathophysiol-
ogy of rosacea (reviewed by Powell, 2005; Marks, 2007;
McAleer et al., 2010; Webster, 2010). The impact of UV
radiation versus heat during sun exposure is still controver-
sial, although clinical experience suggests that both have an
impact because flushing can develop from heat without sun
exposure (e.g., hot steam from a coffee pot (Wilkin, 1981)
and vice versa (sun exposure in a cold environment)).
Moreover, temperature changes modulate vascular func-
tion (Wilkin, 1981, 1983; Crawford et al., 2004) and affect
bacterial protein production (Dahl et al., 2004). Both UV light
and temperature changes can activate sensory nerves (Spiro
et al., 1987; McArthur et al., 1998; Roosterman et al., 2006;
Aubdool and Brain, 2011). Thus, an activated nervous system
in the skin correlates well with the early phase of rosacea,
although it is still unclear whether neuronal activation
precedes or follows the inflammatory infiltrate. The extent
to which the autonomic and/or sensory nervous system
is involved in the neuronal dysregulation during rosacea
has received considerable attention, as modulation of
a-adrenergic receptors or b-adrenergic blockers is helpful in
some patients (Craige and Cohen, 2005; Shanler and Ondo,
2007; Gallo et al., 2010). It is noteworthy that by gene array
analysis and reverse transcriptase PCR we found that
substantial upregulation of proinflammatory genes involved
in vasoregulation (e.g., adrenergic receptors, tryptophan
metabolites, proteases) and neurogenic inflammation (e.g.,
transient receptor potential (TRP) vanilloid receptor 1
(TRPV1), pituitary adenylate cyclase-activating polypeptide),
along with a marked inflammatory infiltrate (Th1 cells,
macrophages, mast cells), can already be observed at a very
early stage of rosacea, even before it is clinically visible in
terms of papules, nodules, or pustules (Figures 1–3). Thus,
despite its origin, early rosacea has to be regarded as an
inflammatory disease characterized by neuroimmune dys-
function and neurovascular dysregulation.
Molecular and immunohistochemical (IHC) characterization
reveals a role of innate and adaptive immunity in rosacea
The PPR subtype of rosacea consists of an inflammatory infil-
trate leading to papules, pustules, and, sometimes even, cysts.
Occasionally, neutrophils or B cells are found in rosacea
biopsies. Various microbial agents, including Demodex folli-
culorum, Helicobacter pylori, Staphylococcus epidermidis,
or Chlamydiae, have been implicated in the pathophysiology
of rosacea (reviewed by Powell, 2005; Lazaridou et al., 2011).
The studies on H. pylori are contradictory (Mc Aleer et al.,
2009; Gallo et al., 2010; Tuzun et al., 2010; Lazaridou et al.,
2011). As for D. folliculorum, recent studies support its role
as a key factor in at least certain subtypes of rosacea,
predominantly subtype II, which is characterized by papules
and pustules. Increased numbers of Demodex mites have
been found in these patients as compared with healthy skin
(Lazaridou et al., 2010). In addition, these mites may harbor
bacteria that may exacerbate rosacea (Lacey et al., 2007;
McAleer et al., 2010). Thus, it is reasonable to hypothesize
that Demodex may activate immune mechanisms in pre-
disposed rosacea patients, in whom Demodex serves as a
trigger factor leading to exacerbation of the papular and/or
pustular phenotype. However, PPR is also found in patients
whose lesions have a normal number of Demodex; other yet
unknown cofactors can be hypothesized.
Our findings of upregulated genes involved in innate
immunity and enhanced immune cells (Figures 1–3) indicate
the involvement of the adaptive and innate immune system
in all subtypes of rosacea, but to different extents. Although
genes of the innate immune response are activated in all three
subtypes of rosacea, the adaptive immune response seems to
be more distinct in PPR and PhR and less in ETR (Figures 1
and 2). This is supported by our IHC characterization of the
inflammatory infiltrate within the various subtypes of rosacea,
suggesting that inflammatory cells of the innate and adaptive
immune system are involved (Figure 3). Our gene array and
morphometric data further reveal three important issues: First,
neutrophils and B cells are only rarely found in certain
patients, indicating that multiple trigger factors lead to the
same symptom (papule, pustule). IL-8 mRNA is significantly
upregulated in PPR, but the trigger that leads to upregula-
tion of IL-8 and thus to neutrophil formation is currently
unknown. Second, gene array and quantitative real-time
RT-PCR data demonstrate upregulation of genes involved in
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Figure 1. Relationship between clinical characteristics and gene array
profile of rosacea. Three clinical subtypes have been studied by gene
array analysis from facial skin biopsies and compared with healthy facial
or uninvolved skin (healthy skin, HS). ETR, erythematotelangiectatic rosacea
(subtype I, RI); PPR, papulopustular rosacea (subtype II, RII); PhR, phymatous
rosacea (subtype III, RIII). (a) ETR is characterized by a prolonged flushing
erythema and teleangiectasia. PPR is characterized by papules and,
more rarely, pustules, in addition to erythema and telangiectasia. PhR is
characterized by fibrotic changes and glandular hyperplasia, less clinically
obvious inflammation, and erythema. Although flushing and discomfort
are the predominant clinical features, and no papules are visible in ETR,
a marked inflammatory infiltrate of CD4þ T lymphocytes, macrophages,
and mast cells is visible already in ETR by immunohistochemistry
(see also Figure 3). (b) Gene array analysis of biopsies from patients with
rosacea (subtypes I–III; n¼ 6–8 patients per subtype) reveals differential
regulation of various selective genes among the various subtypes
(RI¼ ETR¼ cluster II; RII¼ PPR¼ cluster III; RIII¼PhR¼ cluster IV) as
compared with healthy or uninvolved skin (cluster I). Because certain
genes overlap, a developmental ‘‘march’’ from rosacea I to III can
be assumed, although it is not always clinically visible (arrows).
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innate and adaptive immunity, including cathelicidin, which
has been implicated in rosacea pathophysiology by interact-
ing with kallikrein-5 (Yamasaki et al., 2007; Morizane et al.,
2010). Third, the inflammatory infiltrate in ETR is predomi-
nantly perivascular, not periglandular. Accordingly, our gene
array studies and histological data do not support an
important role for known microbial agents in the early phases
of rosacea. However, further investigations about the impact
of the innate immune system on neurovascular and neuroim-
mune function are warranted to fully understand the
neuroimmune and immune defense connection in the
pathophysiology of rosacea.
Molecular and morphological characterization reveals differ-
ences in the inflammatory infiltrate within different rosacea
subtypes
Although various studies indicate that a lymphomonocytic
infiltrate dominates in rosacea, few examined the whole
spectrum of involved inflammatory cells in all subtypes of
rosacea by immunohistochemistry, including morphometry.
Involvement of T cells (Rufli and Buchner, 1984), macro-
phages (Marks and Harcourt-Webster, 1969), mast cells
(Bamford, 2001; Aroni et al., 2008), and neutrophils (Ramelet
and Perroulaz, 1988; Akamatsu et al., 1990; Millikan, 2003)
has been described. Plasma cells have been described in PhR
(Aloi et al., 2000).
Our IHC and morphometric analyses of rosacea subtypes
I–III suggest that the dominating activated cells in rosacea are
CD4þ Th1 cells, macrophages, and mast cells (Figure 3;
Steinhoff et al., 2010; Schwab V et al., 2011). It is noteworthy
that the early stage of rosacea already presents as a Th1-cell-
mediated inflammatory skin disease accompanied by macro-
phages and mast cells, without enhancement of Langerhans
cells, eosinophils, or natural killer cells (Figure 3). Addi-
tional trigger factors not yet known seem to activate neutro-
phils and B cells in rosacea patients under certain conditions,
resulting in pustules (neutrophils) and probably development
into a hyperglandular–phymatous stage (increased density of
B cells).
In contrast with other inflammatory skin diseases such as
psoriasis, lupus erythematosus, or atopic dermatitis, the
crucial cytokines and chemokines that orchestrate the
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Figure 2. Analysis of inflammatory and immune changes in rosacea on the basis of gene array analysis. (a) Biological interpretation of genes upregulated in
cluster II (erythematotelangiectatic rosacea, ETR). Of the 221 known genes that clustered in various dominant biological processes, about 20% can be implicated
in inflammation and immune defense. A surprising and thus far unacknowledged increase of genes involved in alcohol and lipid metabolism was observed.
About 5% of the genes are involved in epidermal activation or development, indicating the involvement of keratinocytes at an early stage of rosacea. (b) Gene
array analysis of cytokines and chemokines involved in the pathophysiology of rosacea indicates a role of interleukin (IL)-7, IL26, and various chemokines
already in early subtypes of rosacea (see Gerber et al., 2011, for details). RI, ETR; RII, papulopustular rosacea (PPR); RIII, phymatous rosacea (PhR). WAP, whey
acidic protein.
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initiation and perpetuation of rosacea are not fully known.
Our molecular characterization of the different subtypes of
rosacea as compared with healthy human skin by gene array
analysis and real-time PCR indicates that a variety of
cytokines, chemokines, metalloproteinases, proteases, and
reactive oxygen species molecules, as well as lipid mediators,
contribute to dysregulation of the inflammatory responses in
rosacea (Figure 2a; Gerber et al. 2011). Still lacking,
however, is a systematic profile of the inflammatory media-
tors involved in rosacea pathophysiology, both at the gene
and protein level.
Molecular and morphological characterization indicates pre-
dominantly vasodilatation, but not angiogenesis in early rosacea
The importance of the vascular cutaneous system in rosacea
is supported by the clinical and histopathological character-
istics of flushing, erythema, and telangiectasia. Furthermore,
edema results from plasma extravasation; i.e., the vascular
leakage of blood vessels and rosacea is characterized by
edema derived from blood and lymphatic vessels. Edema
intensity varies in rosacea, and the maximal clinical stage is
represented by morbus morbihan, in which lymphedema is
the predominant clinical appearance.
Blood and lymphatic vessels have an extraordinary role in
skin development, body homeostasis, and wound repair
(reviewed by Roosterman et al., 2006; Huggenberger and
Detmar, 2011; Meyer-Hoffert and Schro¨der, 2011). Both are
apparently involved in chronic inflammatory diseases such as
psoriasis. Recent data indicate that blood and lymphatic
vessels are also involved in rosacea (Gomaa et al., 2007;
Smith et al., 2007; Aroni et al., 2008; Bender et al., 2008).
The crucial growth factors, vasoregulatory molecules, and
receptors contributing to the development of vasodilatation,
edema formation, or lymphedema are poorly understood in
the context of rosacea (Nakamura and Rockson, 2008;
Ogunbiyi et al., 2011). Although immunoreactivity for
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Figure 3. Histopathological characteristics of rosacea subtypes (erythematotelangiectatic rosacea (ETR), papulopustular rosacea (PPR), phymatous rosacea
(PhR)). All three subtypes were stained for inflammatory and immune markers to determine the inflammatory infiltrate and skin structures involved in
inflammation and fibrosis (T cells: CD4, CD8; B cells: CD20, CD79a; Langerhans cells: CD1a; macrophages: CD68; natural killer cells: CD56; neutrophils:
CD15, elastase; mesenchymal cells: vimentin (VIM); nerves: PGP9.5, NF200; blood vessels: CD31; lymphatic vessels: podoplanin (Podpl)) in the various
subtypes. An increased mast cell infiltrate can also be observed in all subtypes of rosacea (Schwab et al., 2011). (b) Bar¼200 mm; (a, g, i, j, l–o), bar¼ 100 mm;
(c, d, f, h, k, p), bar¼ 50 mm.
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vascular endothelial growth factor, CD31 (blood vessel
marker), and D2-40 (lymphatic vessel marker) has been
described as enhanced in rosacea (Gomaa et al., 2007),
the impact of angiogenetic or vasoregulatory mechanisms
appears to be irrelevant in the pathophysiology of ETR
and PPR. Our combined IHC and morphometric analyses
(Figure 3), together with gene array and RT-PCR studies
(Figures 1 and 2), indicate that blood vessels and lymphatic
vessels are dilated in ETR and PPR and that angiogenesis
and lymphangiogenesis are part of the rosacea patho-
physiology only in the PhR subtype (Schwab et al., 2011).
Flushing can be activated by the autonomic or the sensory
nervous system, although both systems are no longer
completely divided but communicate with each other
(Gibbons et al., 2010; Mousa et al., 2011). The kinetics of
flushing, however, resemble the pattern of sensory C-fiber
activation more. Moreover, non-neuronal mediators such as
lipid metabolites and tryptophan derivates are ultimately
involved in vasoregulation (Wang et al., 2010). Thus,
vasodilatation may be induced by neuronal stimulation, but
could also result from inflammatory mediators released
during the early phase of rosacea, in which inflammatory
cells are already abundantly present (Figure 3; Roosterman
et al., 2006; Graepel et al., 2011).
In rosacea, which is characterized by marked infiltration
of T cells, macrophages, and occasionally neutrophils or B
cells, an important role of blood vascular endothelial cells
lies in their capacity to express selectins and cell adhesion
molecules, which are important for the recruitment of
leukocytes to the site of inflammation (Hua and Cabot,
2010; Muller, 2011). The chemokines involved in the
recruitment of these cells in rosacea are still unknown.
Recently, inhibition of blood vessel activation was found
to exert potent anti-inflammatory properties (reviewed by
Huggenberger et al., 2010; Huggenberger and Detmar, 2011)
and may be a target for anti-inflammatory therapies, even
topically. Activation of lymphatic vessel function via
topically applied vascular endothelial growth factor-C may
be a promising pathway to block inflammation in rosacea
and other diseases (Huggenberger et al., 2010).
NEUROVASCULAR CHANGES IN ROSACEA: THE TRPV1
HYPOTHESIS
The clinical features of rosacea indicate that several body
defense mechanisms are involved in its complex patho-
physiology, reflecting the inflammatory, vascular, neuronal,
and fibrotic components of the different disease subtypes
(Figure 4). The role of the skin nervous system in the control
of inflammation, immunity, and vascular regulation is now
well established (Roosterman et al. 2006). A direct involve-
ment of neurovascular dysregulation in rosacea skin is also
supported by the characteristics of certain cell surface
receptors that are intriguingly activated by trigger factors of
rosacea—namely, spicy food, heat, noxious cold, exercising,
and ethanol—and are simultaneously involved in inflamma-
tion, vasoregulation, and neuronal function, notably the
TRPV1 (Figure 5; see Aubdool and Brain, 2011 for details). It
is noteworthy that rosacea patients present with an enhanced
susceptibility to trigger factors such as ‘‘hot’’ spicy food,
noxious heat and cold, UV radiation, physical exercise,
stress, alcohol (ethanol), and medications (sympathomi-
metics, niacin). Many of these trigger factors activate ion
channels such as TRPV1 (Figure 5; see also Aubdool and
Brain, 2011; Schwab et al., 2011). TRPV1 is expressed by
sensory nerves (Figure 5) and is ultimately involved in
vasoregulation (Caterina et al., 1997; Earley, 2010) and
nociception. Thus, neurovascular dysregulation through
TRPV1 might contribute to the early symptoms of rosacea
characterized by transient flushing (‘‘pre-rosacea’’). This is
also supported by our finding that the density of TRPV1þ
Stimuli:
- Hot environments
- Hot beverages and meals
- Spicy food, ethanol
TRPV1
hyperactivation
Normal response
Pathological response
TRPV1
Over expression?
Neuropeptide
inflammation
Channel sensitization
Reduced activation threshold
Therapeutic intervention:
TRPV1 inactivation
Color code:
Healthy skin
Rosacea skin
Intervention
Block
Na+ Ca2+
Capsaicin Heat
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F
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Figure 4. Potential role of neurogenic inflammation in the early phase of rosacea. Genetic predisposition, along with exogenous or endogenous trigger factors,
stimulates peripheral nerve endings of the skin. Central transmission of neuronal activation leads to facial discomfort (stinging, burning pain), perceived by the
central nervous system. The sensory axon reflex of primary afferents in the dermis and epidermis releases vasoactive neuropeptides such as pituitary adenylate
cyclase-activating polypeptide or vasoactive intestinal peptide (VIP) into the microenvironment. Binding of neuromediators to high-affinity neuropeptide
receptors on arterioles or venules leads to vasodilatation (flushing, erythema) or plasma extravasation (edema). Activation of T cells, macrophages, and mast cells
by neuropeptides results in activation or aggravation of inflammatory responses. It is unknown to what extent neuromediators may also exert anti-inflammatory
capacities in human skin diseases. Bi-directional communication between the innate immune and nervous systems may aggravate early rosacea leading to
chronic disease. Ca2þ , calcium; E, epidermis; F, nerve fibre; Na2þ , sodium; TRPV1, transient receptor potential (TRP) vanilloid receptor 1.
6 Journal of Investigative Dermatology Symposium Proceedings (2011), Volume 15
M Steinhoff et al.
Pathophysiology of Rosacea
nerve fibers is increased in ETR as compared with healthy
skin (Steinhoff M and Voegel JJ, unpublished observation).
Transient flushing later often results in persistent erythema
with dysesthesia (burning, prickling, pain, rarely itch).
Dysesthesia is controlled by sensory A-delta and/or
C-fibers (Steinhoff et al., 2003; Ma, 2010). On this basis,
one may hypothesize that rosacea patients are subjected to a
dysregulation of TRPV1, which is activated by spicy food,
heat, and pH changes (Figure 5). In healthy humans, TRPV1
activation by these trigger factors leads to a short experience
of flushing and burning pain. In rosacea patients, however,
TRPV1 is eventually hyperactive, resulting in sustained
flushing, a feeling of warmth, and ‘‘neurogenic’’ inflam-
mation with edema and inflammatory cell infiltration
(Figure 5), which can be extensive (Scharschmidt et al.,
2011). In accordance with this hypothesis, our own data
confirm that rosacea patients demonstrate a high density of
epidermal and dermal TRPV1þ nerve fibers (Figure 5), as
well as enhanced expression levels of TRPV1 mRNA in skin
biopsies of rosacea patients (Steinhoff M and Voegel JJ,
unpublished observation). Thus, TRPV1 may be a therapeutic
target for rosacea treatment. Other TRPV ion channels are
likely to have a role in rosacea, but further exploration is
needed (see Aubdool and Brain, 2011, for details).
THE RELATIONSHIP OF CHRONIC INFLAMMATION
AND FIBROSIS IN ROSACEA
The PhR rosacea subtype is more common in male patients
and develops mostly from PPR. However, in a certain
subgroup of rosacea patients, PhR is present without obvious
clinical signs of ETR or PPR, probably derived from a
subclinical form of rosacea (Figure 1). The genes and
molecules that may regulate the interaction between the
inflammatory system and the extracellular matrix during the
Pro-inflammatory effects:
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plasma extravasation
edema
Neuropetide release
immunomodulation
Genetic predisposition
+
endogenous triggers:
Spicy food
pH changes
lipids
exercise etc.
Innate immunity
IL-1, IL-8, Chemokines, VEGF, FGF?
LL37, KLK5
TLR2, PAR-2?
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+
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Figure 5. Neurovascular transient receptor potential (TRP) vanilloid receptor 1 (TRPV1) hypothesis in rosacea. TRPV1 localized in abundance on
epidermal and dermal perivascular sensory nerve endings (lower right picture) can be stimulated by various trigger factors of rosacea such as spicy food,
‘‘hot’’ temperature changes, ethanol or inflammatory acidosis, or prostanoids. In healthy humans (black), stimulation of TRPV1 on nerve endings leads to
a transient dilatation, followed by rapid recovery. In rosacea patients (red), overexpression or overstimulation of TRPV1 by a possibly genetic predisposition
leads to neuropeptide release and thereby neurogenic inflammation (see Figure 4 for details), characterized by flushing, erythema, edema, and inflammation.
It is unknown whether TRPV1 dysregulation is based on increased ion channel sensitization or a reduced activation threshold. Thus, therapeutic intervention
of TRPV1 overstimulation may be a new therapeutic strategy in rosacea (green). ETR, erythematotelangiectatic rosacea; FGF, fibroblast growth factor;
KLK5, kallikrein-related peptidase-5; PAR-2, proteinase-activated receptor-2; TLR-2, Toll-like receptor 2; VEGF, vascular endothelial growth factor.
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fibrotic process are poorly understood. Candidates include
reactive oxygen species (Bakar et al., 2007), metalloprotei-
nases (Maatta et al., 2006), serine proteases (Yamasaki et al.,
2011), and growth factors and cytokines/chemokines (re-
viewed by Gallo et al., 2010; Meyer-Hoffert and Schro¨der,
2011; Gerber et al., 2011). On the basis of our knowledge
from other skin diseases or animal models, it appears that
certain receptors for cytokines, chemokines, growth factors,
or proteases are involved in the switch from an inflammatory
to a fibrotic stage (see also Gerber et al., 2011; Meyer-Hoffert
and Schro¨der, 2011). The cellular mechanisms underlying
this switch from inflammation to fibrosis are in general poorly
understood, and for rosacea, completely unknown. Good
candidates for such a ‘‘link’’ between the chronic inflamma-
tory and fibrotic stages appear to be fibroblast growth
factors (Shaw et al., 2010; Craik et al., 2011; Meyer-Hoffert
and Schro¨der, 2011), cytokines (Gerber et al. 2011), and
proteases (Steinhoff et al., 2000, 2005). Future molecular and
cellular characterization of fibroblast growth factors, extra-
cellular matrix proteins, and proteases in the context with
inflammatory changes in rosacea development will shed new
light on disease pathophysiology and potential new treatment
options against rosacea.
Our immunohistological and gene array studies indicate
that fibroblasts are already activated in the earliest stages of
rosacea (Schwab et al., 2011). It remains unclear which cells
and mediators upregulate the function and number of
fibroblasts and myofibroblasts in ETR and PPR before the
phymatous phenotype becomes clinically evident. It is
noteworthy that the observed increased number of fibroblasts
correlates well with enhanced numbers of mast cells (Schwab
et al., 2011), which are known to modulate fibroblast func-
tion and fibrosis (Hermes et al., 2001; Chujo et al., 2009).
Thus, mast cells (Aroni et al., 2008; Schwab et al., 2011)
along with T cells (Rufli and Buchner, 1984; Figure 3) and
macrophages (Marks, 1973, Figure 3) may be ultimately
involved in the development of PhR. Moreover, further
studies indicate that keratinocytes are no longer passive
bystanders in the pathobiology of rosacea but actively
contribute to inflammation and fibrosis by releasing cyto-
kines, chemokines, growth factors, metalloproteinases, and
proteases, and regulate expression of intergrins, occludins,
and claudins (Eslami et al., 2009; Liu et al., 2009;
Huggenberger and Detmar, 2011; Meyer-Hoffert and
Schro¨der, 2011). However, the exact role of keratinocytes,
innate immunity, and epidermal barrier dysregulation in the
context of rosacea still needs to be explored.
Innate immunity and neural receptors as sensors for ‘‘outside
danger’’: potential role in rosacea
Recent evidence indicates that the innate immune system
and epidermal barrier are impaired in rosacea, leading to
increased susceptibility of the skin (‘‘hypersensitive skin’’)
toward toxins, temperature changes, microbe invasion,
tissue injury, UV radiation, and endogenous mediators
(e.g., pH changes, medication, and so on). This activation
of cells involved in skin innate immune regulation and barrier
function may subsequently stimulate the release of mediators
that aggravate inflammatory cascades such as cytokines,
chemokines (Gerber et al. 2011), antimicrobial peptides
(Yamasaki and Gallo, 2011), radical oxygen species (Meyer-
Hoffert and Schro¨der, 2011), neuromediators (Aubdool
and Brain, 2011; Schwab et al., 2011), or proteases (Meyer-
Hoffert and Schro¨der, 2011). Moreover, Toll-like receptor-2
expression is enhanced in rosacea but not in atopic dermatitis
or psoriasis (Yamasaki et al., 2011), indicating a role of
Toll-like receptors in rosacea. Among antimicrobial peptides,
cathelicidin (LL37) appears to have an important role in
innate immunity by regulating inflammation, reactive oxygen
species production, angiogenesis, and protease function
(Yamasaki et al., 2006, 2007). In support of this finding, our
gene array data confirm that mRNA expression levels of LL37
were found to be significantly increased in all subtypes of
rosacea (Schwab et al., 2011). How the various trigger factors
compromise the innate immune system and skin nervous
system needs to be explored. Understanding the role of the
innate immune system and its key factors in rosacea may lead
to new strategies for treatment of rosacea at an early stage
(Meylan et al., 2006; Yamasaki and Gallo, 2009). Recent
findings strongly indicate an important role of antimicrobial
peptides and proteases as ‘‘alarmins’’ (mediators activated in
the skin at an early stage of tissue injury) and are thereby
part of the innate immune system. Upon activation by
trigger factors, they can respond to ‘‘danger’’ molecules
that may impair epidermal homeostasis (reviewed by
Meyer-Hoffert and Schro¨der, 2011; Yamasaki and Gallo,
2011). As peripheral nerves are also part of the
defense system in the epidermal skin barrier, the relationship
among nerves, antimicrobial peptides, and proteases
needs to be further deciphered (Figure 5 and 6; Schwab
et al., 2011).
CONCLUSIONS AND FUTURE DIRECTIONS
The pathophysiology of rosacea is still poorly understood.
Recent cellular, IHC, molecular, and pharmacological
approaches helped to further decipher new molecules and
pathways in the pathobiology of rosacea. Our current
hypothesis (Figure 6) is that a genetic predisposition, together
with trigger factors, leads to the clinical occurrence of
transient flushing, which may be because of overstimu-
lation of the sensory and/or autonomic nervous system
in the skin and induction of innate immune responses.
The concrete relationship between the skin nervous system
and the innate immune system is still unclear. Neurovas-
cular mechanisms are very likely involved in vascular
dysregulation characterized by flushing, persistent erythema,
and telangiectasia. Sustained chronic inflammation charac-
terized by a mainly Th1 macrophage and mast cell-driven
infiltrate further leads to the release of incompletely
understood mediators involved in vasoregulation, immunity,
and fibrosis.
Many details of the new cellular and molecular observa-
tions are still unexplained and raise new critical questions:
(1) What are the roles of the innate and adaptive immune
systems, especially Th1 cells, mast cells, and macrophages,
in the various subtypes? (2) What is the impact of mast cell
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infiltration and activation in all subtypes of rosacea? (3) What
are the roles of the sensory and autonomic nervous system
and which receptors and mediators are involved in inflam-
mation, vasoregulation, and the hypersensitive skin of
rosacea patients? (4) How are the immune and neurovascular
systems linked to each other in terms of disease initiation and
aggravation? (5) Which are the crucial factors initiating the
transient flushing and vasodysregulation? (6) What are the
crucial factors modulating vasodilatation of blood and
lymphatic vessels—are these the same factors and can they
be targeted therapeutically? (7) What is the impact of
keratinocyte and fibroblast activation in rosacea, and could
they be targets for therapy to control inflammation and thus
prevent fibrosis? The many questions reflect our poor
understanding of rosacea and emphasize the need for
advanced scientific approaches, adequate in vivo and ex
vivo models, and preclinical proof-of-principle studies in
rosacea research.
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